ClinicalTrials.gg
Sign In
RecruitingNCT07203833VASO-DIAGUpdated Jan 7, 2026

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

An interventional study of blood sample in Vasorin, Septic Shock and Shock, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens — 6 open to participants now, 7 under way, 2 of them phase 3. Shock, Septic · Centre Hospitalier Universitaire, Amiens.

Started
2025
with 3 others
No phase
3 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens, this one is one of 4 that started in 2025, is one of 3 with no phase, and was the 10th registered.

Shock, Septic

1,078 studies on the registry are indexed under Shock, Septic; 232 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

6 of the 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

France6

All 6 open studies →

Where they have run

France11

Who these studies take

Of the 136 Shock, Septic studies recruiting now, 102 (75%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shock, Septic by Centre Hospitalier Universitaire, Amiens, or all of them as a file.
02

Study summary

Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.

03

Conditions studied

  • Vasorin
  • Septic Shock
  • Shock
  • Biomarker
  • Infection

Keywords

  • Septic shock
  • vasorin
  • Shock
  • Biomarker
  • Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults over 18 years.
  • Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie.
  • Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°>38.3) with a documented or suspected infection
  • Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°\<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Group 1 : No evidence of suspected or documented infection
  • Group 2 : Presence of fever and/or suspected infection
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    in septic shock (infection)

    Biological: blood sample

  • Active comparator
    in shock without sepsis (without infection)

    Biological: blood sample

Interventions

  • Biologicalblood sample

    blood sample in order to measure the concentrations of circulating Vasn

06

What researchers measure

Primary outcomes

  1. Vasn plasma concentration at D0 for each group

    Time frame: day 0

  2. Vasn plasma concentration in each group

    Time frame: day 1

  3. Vasn plasma concentration in each group

    Time frame: day 3

  4. Correlation between Vasn plasma concentration and noradrenaline dose peak in each group

    Time frame: day 0

  5. Correlation between Vasn plasma concentration and noradrenaline dose peak in each group

    Time frame: day 1

  6. Correlation between Vasn plasma concentration and noradrenaline dose peak in each group

    Time frame: day 3

  7. Correlation between Vasn plasma concentration and occurrence of an IRA (KDIGO score) in each group

    Time frame: day 0

  8. Correlation between Vasn plasma concentration and occurrence of an IRA (KDIGO score) in each group

    Time frame: day 1

  9. Correlation between Vasn plasma concentration and occurrence of an IRA (KDIGO score) in each group

    Time frame: day 3

  10. Correlation between Vasn plasma concentration and coagulation marker concentration in each group

    coagulation marker are TF, platelet count, TP, TCA, Factor V, fibrinogen, D-dimers

    Time frame: day 0

  11. Correlation between Vasn plasma concentration and coagulation marker concentration in each group

    coagulation marker are TF, platelet count, TP, TCA, Factor V, fibrinogen, D-dimers

    Time frame: day 1

  12. Correlation between Vasn plasma concentration and coagulation marker concentration in each group

    coagulation marker are TF, platelet count, TP, TCA, Factor V, fibrinogen, D-dimers

    Time frame: day 3

  13. Correlation between Vasn plasma concentration and SOFA score at admission in each group

    Time frame: day 0

  14. Correlation between Vasn plasma concentration and SOFA score at admission in each group

    Time frame: day 1

  15. Correlation between Vasn plasma concentration and mortality in each group

    Time frame: day 3

  16. Correlation between Vasn plasma concentration and SOFA score at admission in each group

    Time frame: day 3

  17. Correlation between Vasn plasma concentration and mortality in each group

    Time frame: day 0

  18. Correlation between Vasn plasma concentration and mortality in each group

    Time frame: day 1

  19. Correlation between Vasn plasma concentration and length of hospitalization in each group

    Time frame: day 1

  20. Correlation between Vasn plasma concentration and length of hospitalization in each group

    Time frame: day 0

  21. Correlation between Vasn plasma concentration and length of hospitalization in each group

    Time frame: day 3

  22. Correlation between Vasn plasma concentration and plasma level of procalcitonin in each group

    Time frame: day 0

  23. Correlation between Vasn plasma concentration and plasma level of procalcitonin in each group

    Time frame: day 1

  24. Correlation between Vasn plasma concentration and plasma level of procalcitonin in each group

    Time frame: day 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

Of 164 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 18 months is below that.

Counting every sponsor, half of 172 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 2, 2025
StartActual
Oct 19, 2025
Primary completionEst.
Apr 2027
CompletionEst.
May 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07203833
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Oct 19, 2025
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Julien Maizel, Pr
Contact
maizel.julien@chu-amiens.fr
33+322087807

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Shock, Septic →

Other studies from this sponsor

Centre Hospitalier Universitaire, Amiens →

Start the discussion